John A. Lewicki insider trades: Mereo BioPharma Group (MREO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 13, 2024 | MREO | ↓ Sell | 16,149 | $4.30 | $69K | Direct | Sep 16, 2024 (3d) |
| Jun 26, 2024 | MREO | ↓ Sell | 24,224 | $3.49 | $84K | Direct | Jun 27, 2024 (1d) |
| Oct 10, 2018 | OMED | ↓ Sell | 1,156 | $2.01 | $2K | Direct | Oct 11, 2018 (1d) |
| Oct 9, 2018 | OMED | ↓ Sell | 2,296 | $2.13 | $5K | Direct | Oct 10, 2018 (1d) |
| Apr 24, 2018 | OMED | ↓ Sell | 4,557 | $2.68 | $12K | Direct | Apr 26, 2018 (2d) |
| Oct 10, 2017 | OMED | ↓ Sell | 1,248 | $4.24 | $5K | Direct | Oct 12, 2017 (2d) |
| Apr 4, 2017 | OMED | ↓ Sell | 5,754 | $9.06 | $52K | Direct | Apr 5, 2017 (1d) |
| Jan 3, 2017 | OMED | ↓ Sell | 9,175 | $7.63 | $70K | Direct | Jan 5, 2017 (2d) |
| Jan 7, 2016 | OMED | ↓ Sell | 2,162 | $22.28 | $48K | Direct | Jan 8, 2016 (1d) |
| Jun 16, 2015 | OMED | ↓ Sell | 17,000 | $25.07 | $426K | Direct | Jun 17, 2015 (1d) |
| Apr 2, 2015 | OMED | ↓ Sell | 17,000 | $25.28 | $430K | Direct | Apr 3, 2015 (1d) |
| Feb 2, 2015 | OMED | ↓ Sell | 4,000 | $22.49 | $90K | Direct | Feb 4, 2015 (2d) |
| Jan 2, 2015 | OMED | ↓ Sell | 4,000 | $22.10 | $88K | Direct | Jan 5, 2015 (3d) |
| Dec 1, 2014 | OMED | ↓ Sell | 4,000 | $21.19 | $85K | Direct | Dec 3, 2014 (2d) |
| Nov 3, 2014 | OMED | ↓ Sell | 4,000 | $20.45 | $82K | Direct | Nov 5, 2014 (2d) |
| Oct 2, 2014 | OMED | ↓ Sell | 5,809 | $20.00 | $116K | Direct | Oct 3, 2014 (1d) |
| Sep 2, 2014 | OMED | ↓ Sell | 2,191 | $20.00 | $44K | Direct | Sep 3, 2014 (1d) |
| Aug 1, 2014 | OMED | ↓ Sell | 4,000 | $20.98 | $84K | Direct | Aug 4, 2014 (3d) |
| Jul 1, 2014 | OMED | ↓ Sell | 4,000 | $23.86 | $95K | Direct | Jul 3, 2014 (2d) |
| Jun 16, 2014 | OMED | ↓ Sell | 4,000 | $24.59 | $98K | Direct | Jun 17, 2014 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About John A. Lewicki's insider trades
John A. Lewicki is Chief Scientific Officer at Mereo BioPharma Group (MREO). Since Jun 16, 2014, John has reported no open-market purchases and 20 sales worth $2.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (14 filings), option exercises (14 filings), gifts (3 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MREO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.